Statistics for PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review
Total visits
| views | |
|---|---|
| PCN14 A Pharmacoeconomic Appraisal of Cabazitaxel Versus Abiraterone for the Second-Line Treatment of Patients with Metastatic Hormone-Refractory Prostate Cancer (MHRPC) Progressing After the Treatment with Docetaxel: a Systematic Review | 6 |
Total visits per month
| views | |
|---|---|
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 1 |
| September 2024 | 0 |
| October 2024 | 5 |
| November 2024 | 0 |
| December 2024 | 0 |